advanced small cell lung cancer
About
SCLC is a neuroendocrine tumor with a very high degree of malignancy. It is closely related to smoking, with about 95% of patients having a history of smoking. Core dilemmas: ① Lack of classic drug-driven mutations such as EGFR, ALK, ROS1;② The primary resistance rate to immunotherapy is about 60%, and PD-1/PD-L1 inhibitors can only provide limited survival benefits;③ A large number of immunosuppressive cells in the tumor microenvironment hinder the efficacy of immunotherapy.
Features & Symptoms
- high malignancy
- Distant metastasis can occur early
- Initially sensitive to chemotherapy but highly resistant
- Lack of classic available drugs drives mutations
Treatment Options
| Treatment | Description | Stage | Price Range |
|---|---|---|---|
| Bispecific antibody + immune combination | DLL3-targeted bispecific antibody (tarlatamab) combined with Atezolizumab has shown breakthrough efficacy in recurrent SCLC and will be approved by the FDA for accelerated approval in 2024. | FDA批准/Phase II/III | $120K - $400K/年 |
| ADC drug | Antibody-conjugated drugs targeting DLL3, such as a modified version of rovalpituzumab tesirine, have shown some efficacy in SCLC. | Phase II | $180K - $500K/疗程 |
Prognosis
Broad median survival period is 8-10 months, and the 5-year survival rate is approximately 4%
Additional Notes
Notes: Front-line treatment: The first line of extensive SCLC criteria is PD-L1 inhibitors (Atelizumab or Durvalimumab) in combination with platinum + etoposide; DLL3 targeting: Tarlatamab (Double anti-DLL3/CD3) has been approved for treatment in SCLC, and DLL3 expression needs to be evaluated before treatment; Brain metastasis screening: The incidence of brain metastases in SCLC is as high as 50%, and regular cranial MRI examinations are required at the time of diagnosis and during follow-up; Preventive cranial irradiation (PCI): PCI may be considered for patients with extensive SCLC after complete remission; Smoking cessation: Smoking cessation can improve treatment response and overall prognosis.; Exclusive service commitment: The platform will allocate a dedicated medical team to each patient to assist in dismantling and properly deploying the following precautions throughout the process. When cross-state and cross-border diagnosis and treatment projects or drugs are involved, the platform will make overall arrangements for the entire docking; for disabled and semi-disabled patient groups, the platform will provide rush-free alternative solutions (including remote consultation, door-to-door sampling, direct drug delivery in the cold chain, etc.), to ensure that patients can get the same high-quality diagnosis and treatment resources without having to travel in person.; Study phase: Phase II/III clinical. Prognosis: Broad interim survival period is 8-10 months, and the 5-year survival rate is about 4%.
Frequently Asked Questions
What is advanced small cell lung cancer?
SCLC is a neuroendocrine tumor with a very high degree of malignancy. It is closely related to smoking, with about 95% of patients having a history of smoking. Core dilemmas: ① Lack of classic drug-driven mutations such as EGFR, ALK, ROS1;② The primary resistance rate to immunotherapy is about 60%, and PD-1/PD-L1 inhibitors can only provide limited survival benefits;③ A large number of immunosuppressive cells in the tumor microenvironment hinder the efficacy of immunotherapy.
What are the symptoms of advanced small cell lung cancer?
high malignancy,Distant metastasis can occur early,Initially sensitive to chemotherapy but highly resistant,Lack of classic available drugs drives mutations
How is advanced small cell lung cancer treated?
Bispecific antibody + immune combination: DLL3-targeted bispecific antibody (tarlatamab) combined with Atezolizumab has shown breakthrough efficacy in recurrent SCLC and will be approved by the FDA for accelerated approval in 2024.; ADC drug: Antibody-conjugated drugs targeting DLL3, such as a modified version of rovalpituzumab tesirine, have shown some efficacy in SCLC.
What is the prognosis for advanced small cell lung cancer?
Broad median survival period is 8-10 months, and the 5-year survival rate is approximately 4%